OBIO
Orchestra BioMed Holdings, Inc.
$4.10
+0.74%
$245.5M
No data for this timeframe.
Vol
Market Cap$245.5M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (85%)
Inst. Holders28 funds
Inst. Value$59.2M
Inst. Activity3 buys / 4 sells
Insider Activity6B / 2S
Insider Net $$142.8K
SEC Reports3
Press Releases2
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001814114·Prev Close $4.07
Recent Activity
Jun 10, 2026
Insider
Taylor Andrew Lawrence surrendered for taxes 36,352 shares
Chief Financial Officer @ $4.02 ($146.1K)
Jun 10, 2026
Insider
Hochman David P surrendered for taxes 3,283 shares
See Remarks @ $4.02 ($13.2K)
Jun 10, 2026
Insider
Hochman David P surrendered for taxes 3,283 shares
See Remarks @ $4.02 ($13.2K)
Jun 2, 2026
SEC
Two insiders at Orchestra BioMed traded in opposite directions on the same day: Director Hochman bought $19K worth of sh
CLUSTER — Impact 2/10
Jun 2, 2026
other
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc
May 19, 2026
SEC
Two directors and one officer made small open-market purchases of OBIO shares totaling ~$136K, representing only ~0.06%
CLUSTER — Impact 2/10
Apr 29, 2026
SEC
Orchestra BioMed Holdings, Inc. filed definitive additional proxy materials for its 2026 Annual Meeting, scheduled for J
DEFA14A — Impact 2/10
Inst.
Point72 Asset Management, L.P. — TRIM
87,888 shares ($373.5K)
Price Targets
$12.17
+196.7% upside
Strong Buy
Current $4.10
Low $9.00
Median $10.00
High $20.00
6 analysts
$9.00
$20.00
Analyst Ratings
3Strong Buy
8Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 19, 2026 | B. Riley Securities | MAINTAIN | Buy → Buy |
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Jan 9, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.37 ▲ +16.0% | $-0.41 — $-0.28 | 26% YoY | 5 |
| Next Q | $-0.38 ▲ +13.0% | $-0.43 — $-0.32 | 4% YoY | 5 |
| Current FY | $-1.50 | $-1.60 — $-1.30 | -35% YoY | 5 |
| Next FY | $-1.46 | $-1.81 — $-1.10 | 3% YoY | 6 |
Latest Reports
NEUTRAL
CLUSTER
2/10
Two insiders at Orchestra BioMed traded in opposite directions on the same day: Director Hochman bought $19K worth of sh
Jun 2, 2026
NEUTRAL
CLUSTER
2/10
Two directors and one officer made small open-market purchases of OBIO shares totaling ~$136K, representing only ~0.06%
May 19, 2026
BULLISH
Press
7/10
Orchestra BioMed presented new clinical data from its MODERATO II trial showing AVIM Therapy delivered an immediate 13.2
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RTW INVESTMENTS, LP | $35.3M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $9.4M | — |
| Alyeska Investment Group, L.P. | $4.3M | TRIM |
| BlackRock, Inc. | $2.7M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.1M | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | Taylor Andrew | F | $146.1K |
| Jun 10, 2026 | Hochman David | F | $13.2K |
| Jun 10, 2026 | Hochman David | F | $13.2K |
| Jun 1, 2026 | Sherman Darren | SELL | $58.0K |
| Jun 1, 2026 | Hochman David | BUY | $19.1K |
28 institutional holders with $59.2M total value (13,918,788 shares) as of 2026-Q1. Top holders: RTW, VANGUARD, Alyeska. Net selling activity: 4 institutions trimmed/exited vs 3 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 8,306,063 | $35.3M | 59.7% | ADD +46.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,204,319 | $9.4M | 15.8% | — |
| 3 | Alyeska Investment Group, L.P. | 1,000,000 | $4.3M | 7.2% | TRIM -26.8% |
| 4 | BlackRock, Inc. | 635,714 | $2.7M | 4.6% | — |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 265,499 | $1.1M | 1.9% | ADD +46.2% |
| 6 | VANGUARD FIDUCIARY TRUST CO | 235,214 | $999.7K | 1.7% | — |
| 7 | MARSHALL WACE, LLP | 188,484 | $801.1K | 1.4% | — |
| 8 | STATE STREET CORP | 169,410 | $720.0K | 1.2% | ADD +57.9% |
| 9 | GOLDMAN SACHS GROUP INC | 155,242 | $659.8K | 1.1% | — |
| 10 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 97,521 | $414.5K | 0.7% | — |
| 11 | Point72 Asset Management, L.P. | 87,888 | $373.5K | 0.6% | TRIM -45.7% |
| 12 | CITADEL ADVISORS LLC | 79,185 | $336.5K | 0.6% | — |
| 13 | Hudson Bay Capital Management LP | 71,134 | $302.3K | 0.5% | ADD +43.9% |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 70,900 | $301.3K | 0.5% | TRIM -53.1% |
| 15 | TWO SIGMA INVESTMENTS, LP | 60,107 | $255.5K | 0.4% | — |
| 16 | BARCLAYS PLC | 59,342 | $252.2K | 0.4% | NEAR_EXIT -99.9% |
| 17 | BANK OF AMERICA CORP /DE/ | 52,761 | $224.2K | 0.4% | DOUBLED +200.7% |
| 18 | Brevan Howard Capital Management LP | 36,769 | $156.3K | 0.3% | — |
| 19 | MORGAN STANLEY | 35,639 | $151.5K | 0.3% | TRIM -56.5% |
| 20 | CITIGROUP INC | 25,529 | $108.5K | 0.2% | DOUBLED +227.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | TRIM | 161,946 | 87,888 | -45.7% | $373.5K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 49,425 | 71,134 | +43.9% | $302.3K | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 151,300 | 70,900 | -53.1% | $301.3K | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 17,547 | 52,761 | +200.7% | $224.2K | 2026-Q1 |
| MORGAN STANLEY | TRIM | 81,851 | 35,639 | -56.5% | $151.5K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | NEAR_EXIT | 67,100 | 16,200 | -75.9% | $68.8K | 2026-Q1 |
| CANADA PENSION PLAN INVESTMENT BOARD | ADD | 7,100 | 11,300 | +59.2% | $48.0K | 2026-Q1 |
| Alyeska Investment Group, L.P. | TRIM | 1,365,482 | 1,000,000 | -26.8% | $4.2M | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 180,439 | 263,788 | +46.2% | $1.1M | 2025-Q4 |
| STATE STREET CORP | ADD | 100,733 | 159,033 | +57.9% | $660.0K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 380,508 | 151,300 | -60.2% | $627.9K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 10,323 | 81,851 | +692.9% | $339.7K | 2025-Q4 |
| TD ASSET MANAGEMENT INC | TRIM | 92,678 | 45,692 | -50.7% | $189.6K | 2025-Q4 |
| Cresset Asset Management, LLC | TRIM | 30,000 | 20,000 | -33.3% | $83.0K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 31,119 | 17,547 | -43.6% | $72.8K | 2025-Q4 |
| CWM, LLC | NEAR_EXIT | 381 | 2 | -99.5% | — | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 1,157,317 | 1,481,875 | +28.0% | $3.7M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 169,400 | 380,508 | +124.6% | $943.7K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 138,591 | 180,439 | +30.2% | $447.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 21,577 | 31,119 | +44.2% | $77.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 26,139 | 3,815 | -85.4% | $9.5K | 2025-Q3 |
| BARCLAYS PLC | NEAR_EXIT | 874 | 1 | -99.9% | $2.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 216,985 | 138,591 | -36.1% | $371.4K | 2025-Q2 |
| STATE STREET CORP | TRIM | 473,719 | 130,133 | -72.5% | $348.8K | 2025-Q2 |
| UBS Group AG | ADD | 17,270 | 26,139 | +51.4% | $70.1K | 2025-Q2 |
8 unique insiders with 24 transactions. Net insider value: $142.8K ($201.0K bought, $58.2K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | Taylor Andrew Lawrence | Chief Financial Officer | TAX W/H | 36,352 | $4.02 | $146.1K |
| Jun 10, 2026 | Hochman David P | See Remarks | TAX W/H | 3,283 | $4.02 | $13.2K |
| Jun 10, 2026 | Hochman David P | See Remarks | TAX W/H | 3,283 | $4.02 | $13.2K |
| Jun 1, 2026 | Sherman Darren | See Remarks | SELL | 15,000 | $3.87 | $58.0K |
| Jun 1, 2026 | Hochman David P | See Remarks | BUY | 5,000 | $3.83 | $19.1K |
| May 28, 2026 | Sherman Darren | See Remarks | TAX W/H | 4,925 | $3.98 | $19.6K |
| May 28, 2026 | Taylor Andrew Lawrence | Chief Financial Officer | TAX W/H | 3,076 | $3.98 | $12.2K |
| May 18, 2026 | Aryeh Jason | Director | BUY | 665 | $3.75 | $2.5K |
| May 15, 2026 | Hochman David P | See Remarks | BUY | 5,000 | $3.77 | $18.9K |
| May 15, 2026 | Aryeh Jason | Director | BUY | 8,971 | $3.90 | $35.0K |
| May 14, 2026 | Fain Eric S | Director | BUY | 20,000 | $4.13 | $82.6K |
| Apr 27, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | EXERCISE | 1,250,032 | $0.000100 | $125.00 |
| Apr 27, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | SELL | 32 | $4.13 | $132.16 |
| Apr 27, 2026 | RTW INVESTMENTS, LP | 10%+ Owner | EXERCISE | 1,250,032 | $2.75 | $3.4M |
| Mar 25, 2026 | Aiello Joshua | Principal Accounting Officer | TAX W/H | 241 | $4.57 | $1.1K |
| Mar 25, 2026 | Sherman Darren | See Remarks | TAX W/H | 33,317 | $4.57 | $152.3K |
| Mar 25, 2026 | Hochman David P | See Remarks | TAX W/H | 32,438 | $4.57 | $148.2K |
| Mar 13, 2026 | Hochman David P | See Remarks | BUY | 10,000 | $4.29 | $42.9K |
| Feb 12, 2026 | Taylor Andrew Lawrence | Chief Financial Officer | AWARD | 181,000 | — | — |
| Feb 12, 2026 | Sherman Darren | See Remarks | AWARD | 397,000 | — | — |
| Feb 12, 2026 | Aiello Joshua | Principal Accounting Officer | AWARD | 70,000 | — | — |
| Feb 12, 2026 | Hochman David P | See Remarks | AWARD | 504,000 | — | — |
| Feb 5, 2026 | Cleary Chris | Director | TAX W/H | 676 | $3.71 | $2.5K |
| Jan 28, 2026 | Sherman Darren | See Remarks | AWARD | 34,974 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 3 neutral. Avg impact: 2.0/10.
NEUTRAL
CLUSTER
2/10
Two insiders at Orchestra BioMed traded in opposite directions on the same day: Director Hochman bou
Jun 2, 2026
NEUTRAL
CLUSTER
2/10
Two directors and one officer made small open-market purchases of OBIO shares totaling ~$136K, repre
May 19, 2026
NEUTRAL
DEFA14A
2/10
Orchestra BioMed Holdings, Inc. filed definitive additional proxy materials for its 2026 Annual Meet
Apr 29, 2026
Current analyst consensus: Strong Buy (85% buy). Based on 13 analysts: 3 strong buy, 8 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.17 mean target
+196.7% upside
Strong Buy (1.43)
$9.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $4.10 |
| Target Low | $9.00 |
| Target Mean | $12.17 |
| Target Median | $10.00 |
| Target High | $20.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.37 | $-0.41 | $-0.28 | 25.6% | +16.0% | 4↑ 1↓ | $0.0B | -85.7% | 5 |
| Next Q 2026-09-30 |
$-0.38 | $-0.43 | $-0.32 | 4.0% | +13.0% | 3↑ 1↓ | $0.0B | -86.9% | 5 |
| Current FY 2026-12-31 |
$-1.50 | $-1.60 | $-1.30 | -34.8% | — | 5↑ 0↓ | $0.0B | -98.6% | 5 |
| Next FY 2027-12-31 |
$-1.46 | $-1.81 | $-1.10 | 2.5% | — | 2↑ 0↓ | $0.0B | 38.8% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.372 | |
| 7d ago | $-0.391 | +0.019 |
| 30d ago | $-0.443 | +0.071 |
| 60d ago | $-0.443 | +0.071 |
| 90d ago | $-0.398 | +0.026 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 19, 2026 | B. Riley Securities | MAINTAIN | Buy | Buy |
| May 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 13, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Mar 12, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Jan 9, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 8 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 3 | 9 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 2, 2026
other
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Compa
May 19, 2026
other
Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference
<p align="justify">NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company
May 18, 2026
earnings_calendar
OBIO Q1 2026 Earnings Scheduled — 2026-05-18
May 12, 2026
earnings
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
<p align="justify">NEW HOPE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company
May 11, 2026
earnings_calendar
OBIO Q1 2026 Earnings Scheduled — 2026-05-11
May 6, 2026
other
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
<p align="justify">NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Compan
May 4, 2026
earnings_calendar
OBIO Q1 2026 Earnings Scheduled — 2026-05-04
Apr 23, 2026
fda
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
<p align="justify">NEW HOPE, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Comp
Mar 12, 2026
earnings
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
<p align="justify">NEW HOPE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Comp
Mar 3, 2026
other
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
<p align="justify">NEW HOPE, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Comp